Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02947711 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects
A Phase 1 study, sponsored by Eisai Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02947711 is a Phase 1 study that has completed, run by Eisai Co.. The registered enrollment target is 16 participants.
The verdict
NCT02947711, a Phase 1 study, has completed, sponsored by Eisai Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein \[Pgp\] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in healthy participants.
Interventions
- DRUG E2027
- DRUG Diltiazem ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02947711
The ClinicalTrials.gov registry entry for NCT02947711 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which E2027 is the first listed.
NCT02947711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02947711 about?
NCT02947711 is a clinical study titled "Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects". This Phase 1, open-label, single-sequence, drug-drug Interaction study is conducted to evaluate the effect of diltiazem extended release (ER) (a moderate CYP3A inhibitor and P glycoprotein \[Pgp\] inhibitor) on the pharmacokinetics (PK) of a single oral dose of E2027 in healthy participants.
What is the current status of trial NCT02947711?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2016-10. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02947711?
The interventions under investigation include: E2027 (DRUG), Diltiazem ER (DRUG).
Who is sponsoring clinical trial NCT02947711?
This trial is sponsored by Eisai Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.